CURATEK's TOPICAL METROGEL (METRONIDAZOLE) GETS ORPHAN DESIGNATION
CURATEK's TOPICAL METROGEL (METRONIDAZOLE) GETS ORPHAN DESIGNATION as treatment for acne rosacea, the company announced March 9. The firm estimates that approximately 140,000 patients in a given year suffer from acne rosacea, or "adult acne," a chronic inflammation of the facial skin accompanied by dilated or enlarged blood vessels. Describing the orphan disease, Curatek noted that it causes the nose to become red and enlarged "in extreme cases," a condition called rhinophyma. The company is a privately held company based in Elk Grove Village, Illinois. In a press statement, Curatek said it "specializes in the development and marketing of new ethical pharmaceutical products for dermatology and other therapeutic areas." Curatek filed its NDA for MetroGel in late 1987. The company said clinical studies, which have been completed, showed the drug to be "safe and effective in the treatment of rosacea, including cases where other drugs had failed." To date the most common treatment for rosacea has been the use of oral antibiotics to reduce inflammatory symptoms, Curatek noted. Metronidazole, a synthetic antibacterial, is off patent and currently available only in oral and I.V. form. The leading brand, Searle's Flagyl, is indicated for several types of infections, including anaerobic bacterial infections, amebiasis, and trichomoniasis. Upon approval, Curatek's topical MetroGel will receive seven years of exclusive marketing for the acne rosacea indication under the Orphan Drug Act.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth